Diagnostic procedures using direct injection of gaseous hyperpolarized 129Xe and associated systems and products
First Claim
1. A method of screening for the presence of a pulmonary embolism, comprising the steps of:
- positioning a subject having a pulmonary region and a blood circulation path including veins and arteries in an NMR system, the subject'"'"'s pulmonary region having pulmonary veins and pulmonary arteries and associated vasculature defining a pulmonary portion of the circulation path;
injecting a first quantity of polarized gaseous 129Xe directly into at least one vein of the subject;
obtaining NMR signal data associated with the polarized 129Xe in the pulmonary region of the subject, the signal data including information corresponding to the polarized gas introduced in said injecting step;
generating an MRI image having spatially coded visual representation of the NMR signal data; and
identifying the presence of at least one condition of blockage, restriction, abnormality, and substantially unobstructed free passage of the pulmonary circulation path.
5 Assignments
0 Petitions
Accused Products
Abstract
A method of screening for pulmonary embolism uses gaseous phase polarized 129Xe which is injected directly into the vasculature of a subject. The gaseous 129Xe can be delivered in a controlled manner such that the gas substantially dissolves into the vasculature proximate to the injection site. Alternatively, the gas can be injected such that it remains as a gas in the bloodstream for a period of time (such as about 8-29 seconds). The injectable formulation of polarized 129Xe gas is presented in small quantities of (preferably isotopically enriched) hyperpolarized 129Xe and can provide high-quality vasculature MRI images or NMR spectroscopic signals with clinically useful signal resolution or intensity. One method injects the polarized 129Xe as a gas into a vein and also directs another quantity of polarized gas into the subject via inhalation. In this embodiment, the perfusion uptake allows arterial signal information and the injection (venous side) allows venous signal information. The dual delivery is used to generate a combined introduction path with a more complete image signal of both the arterial and venous side of the pulmonary vasculature. In this NMR imaging method, the pulmonary embolism screening method can use the same NMR chest coil for the excitation and detection of the 129Xe signals. The direct injection of small quantities of gas at particular sites along the vasculature targets specific target regions to provide increased signal intensity NMR images. The disclosure also includes related methods directed to other diagnostic vasculature regions physiological and conditions. Associated delivery and dispensing systems and methods, containers, and quantitative formulations of the polarized gas are also described.
-
Citations
88 Claims
-
1. A method of screening for the presence of a pulmonary embolism, comprising the steps of:
-
positioning a subject having a pulmonary region and a blood circulation path including veins and arteries in an NMR system, the subject'"'"'s pulmonary region having pulmonary veins and pulmonary arteries and associated vasculature defining a pulmonary portion of the circulation path;
injecting a first quantity of polarized gaseous 129Xe directly into at least one vein of the subject;
obtaining NMR signal data associated with the polarized 129Xe in the pulmonary region of the subject, the signal data including information corresponding to the polarized gas introduced in said injecting step;
generating an MRI image having spatially coded visual representation of the NMR signal data; and
identifying the presence of at least one condition of blockage, restriction, abnormality, and substantially unobstructed free passage of the pulmonary circulation path. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 29)
-
-
24. A method of enhancing the resolution of MRI-based medical images, comprising the steps of:
-
injecting directly into an injection site associated with a subject a first quantity of polarized 129Xe in gaseous form during an NMR imaging session;
delivering a second quantity of polarized gas product to the subject within the same imaging session as said injecting step, the second quantity being larger than the first quantity; and
generating an MRI image corresponding to the excitation of the first and second quantities of polarized gas introduced in said injecting and delivering steps. - View Dependent Claims (25, 26, 27, 28, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 44, 45)
-
-
42. A method of obtaining diagnostic images of the cranial region, comprising the steps of:
-
injecting less than about 5 cc'"'"'s of 129Xe polarized gas into an injection site in a carotid artery;
dissolving said polarized 129Xe gas into the vasculature proximate to the injection site; and
generating an NMR image having signal intensity associated with the NMR excitation of the dissolved injected 129Xe. - View Dependent Claims (43)
-
- 46. A method of facilitating bubble dissipation associated with the injection of polarized gaseous 129Xe, comprising the step of introducing in vivo a physiologically acceptable surfactant temporally proximate to the in vivo injection of a quantity of hyperpolarized gas.
-
47. A method of obtaining an MR image, comprising the steps of:
-
injecting less than about 100 cc'"'"'s of gaseous hyperpolarized 129Xe in vivo into the vasculature of a mammalian subject; and
generating a NMR signal corresponding to the injected quantity of hyperpolarized 129Xe gas. - View Dependent Claims (50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)
-
-
64. A method of evaluating the efficacy of targeted drug therapy, comprising the steps of:
-
delivering a quantity of a predetermined gene treatment preparation or pharmaceutical drug in vivo into a mammalian subject having a target site and a treatment condition;
injecting a predetermined quantity of gaseous phase hyperpolarized 129Xe in vivo into a mammalian subject such that the hyperpolarized gas is delivered to the target site in gaseous or dissolved form;
generating a NMR image or spectroscopic signal of the target site associated with the injected hyperpolarized 129Xe gas; and
evaluating the NMR image or spectroscopic signal to evaluate the efficacy of the gene treatment or drug on the treatment condition administered in said delivering step. - View Dependent Claims (65, 66, 67, 68, 69)
-
-
70. A method of determining the presence of cancerous tissue, comprising the steps of:
-
delivering a quantity of a pharmaceutical drug in vivo into a mammalian subject having a target site associated with a suspect mass or tissue abnormality;
injecting a quantity of gaseous hyperpolarized 129Xe in vivo into a mammalian subject such that the hyperpolarized gas is delivered to the target site;
generating a NMR image or spectroscopic signal of the target site corresponding to the injected hyperpolarized 129Xe gas; and
evaluating the NMR image or signal for the presence or absence of signature patterns in the generated image or signal associated with the presence or absence of cancer. - View Dependent Claims (71)
-
-
72. An injectable 129Xe gas product, said 129Xe gas product formulated as a sterile non-toxic hyperpolarized gas formulation which consists essentially of isotopically enriched 129Xe in gaseous phase which is injected in vivo in a quantity of less than about 20 cubic centimeters.
-
73. An injectable 129Xe gas pharmaceutical grade product, said product formulated as a sterile non-toxic product which consists essentially of 129Xe in gaseous phase and traces of CO2, wherein said injectable gas product is configured to be dispensed in vivo.
-
74. An syringe, comprising:
-
a primary gas holding chamber having inner and outer surfaces;
a plunger sized and configured to be received within said primary gas holding chamber, wherein said plunger has a gas contacting surface;
a quantity of hyperpolarized noble gas held in said primary gas holding chamber;
a valve member operably associated with said primary gas holding chamber; and
a capillary stem positioned intermediate of said plunger and said valve member in fluid communication with said primary gas holding chamber wherein said primary gas holding chamber includes a wall having outer and inner surfaces, and wherein said primary gas holding chamber inner surface and said plunger gas contacting surface are formed from a material which inhibits contact induced polarization decay associated therewith. - View Dependent Claims (75, 76, 77, 78, 79)
-
-
80. A method of preparing a gas container having a sealable gas holding chamber prior to the introduction of a polarized product therein, comprising the steps of:
-
(a) evacuating the gas container;
(b) introducing a quantity of CO2 gas therein; and
(c) repeating step (a) after step (b).
-
-
81. A method of sizing the length of a capillary stem on a container having a primary hyperpolarized gas holding chamber with a volume, the capillary stem having a volume which is substantially less than that of the gas holding chamber and includes a wall defining a flow channel aperture having a radius or width and a length, the wall having a gas contacting surface formed of a material having a relaxivity value for a selected hyperpolarized gas associated therewith, the method comprising the steps of:
-
defining a capillary stem aperture size;
determining the type of hyperpolarized gas to be held in the container and a diffusion coefficient associated therewith;
establishing a relaxivity value for the material forming the capillary wall; and
calculating an optimal capillary stem length. - View Dependent Claims (82)
-
-
83. A container, comprising:
-
a primary gas holding chamber having a primary volume associated therewith;
a capillary stem having a wall with a gas contacting surface, a flow aperture, a length, and a capillary volume, said capillary stem in fluid communication with said gas holding chamber, wherein said gas contacting surface of said wall has a relaxivity value for a selected hyperpolarized gas associated therewith; and
a quantity of hyperpolarized gas held in said gas holding chamber;
wherein said capillary stem length is selected to substantially correspond to an optimal length to improve the polarization life of the hyperpolarized gas held therein, and wherein the optimal length is calculated based on a desired T1, the width of the capillary flow aperture, and the relaxivity value. - View Dependent Claims (84, 85)
-
-
86. An injection system for administering polarized gas to a subject, comprising:
-
a polarized noble gas supply;
a catheter configured and sized for intravenous or intrarterial placement in a subject in fluid communication with the supply of polarized noble gas; and
an injection head positioned in a distal portion of the catheter, wherein said injection head comprises multiple orifices having a width of between about 1 nm-50 μ
m, configured so that, in operation, hyperpolarized gas flows therethrough and out of the catheter into the subject. - View Dependent Claims (87, 88)
-
Specification